CMPS will retrace at least 60% of its May 30 gains within 10 trading days, absent a confirmed Phase 3 data readout or partnership announcement.

Compass Pathways (ticker CMPS) had its stock price jump on May 30, but there was no obvious news reason for it—just retail trader enthusiasm. History shows that small biotech stocks that spike on no real catalyst usually come crashing back down within days or weeks. This prediction says the stock will lose at least 60% of those gains within two weeks unless the company announces actual trial results or a major partnership deal.

No confirmed catalyst for the May 30 spike. Retail momentum pattern with institutional discrimination evident (NUMI flat same day). Psychedelic biotech sector has consistent history of sharp post-spike reversions without clinical anchors. The 60% threshold and 10-trading-day window are precisely measurable. Confidence reflects strong base rate for unanchored small-cap biotech spikes reversing, tempered by tail risk of surprise announcement.